<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02949999</url>
  </required_header>
  <id_info>
    <org_study_id>AUR-VCS-2015-J01</org_study_id>
    <nct_id>NCT02949999</nct_id>
  </id_info>
  <brief_title>Voclosporin in Healthy Japanese Volunteers</brief_title>
  <official_title>A Single-center, Double-blind, Placebo-controlled, Randomized, Ascending Multiple-dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Voclosporin in Healthy Japanese Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aurinia Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aurinia Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a single-centre, double-blind, placebo controlled, randomized, ascending&#xD;
      multiple dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamic&#xD;
      profiles of voclosporin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ten subjects will be randomized into each of four treatment groups to receive approximately&#xD;
      0.25, 0.5, 1.0, 1.5mg/kg/dose of voclosporin vs placebo. For Day 1, subjects will be given&#xD;
      oral treatment once a day; Day 2, subjects will not be given any oral treatment; Day 3-12,&#xD;
      subjects will be given oral treatment twice a day; Day 13, subjects will be given oral&#xD;
      treatment once a day. The duration of the study takes about 21 days (including follow up&#xD;
      assessments).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events</measure>
    <time_frame>21 days</time_frame>
    <description>Tolerability of voclosporin after single and multiple oral ascending doses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean, median and standard deviation of laboratory parameters. Incidence of laboratory parameters outside of normal range</measure>
    <time_frame>21 days</time_frame>
    <description>Safety of voclosporin after single and multiple oral ascending doses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of voclosporin after single and multiple oral ascending doses</measure>
    <time_frame>21 days</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of voclosporin after single and multiple oral ascending doses</measure>
    <time_frame>21 days</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Volunteers</condition>
  <arm_group>
    <arm_group_label>0.25mg/kg voclosporin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25mg/kg voclosporin BID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5mg/kg voclosporin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5mg/kg voclosporin BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0mg/kg voclosporin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0mg/kg voclosporin BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.5mg/kg voclosporin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5mg/kg voclosporin BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo voclosporin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voclosporin</intervention_name>
    <arm_group_label>0.25mg/kg voclosporin</arm_group_label>
    <arm_group_label>0.5mg/kg voclosporin</arm_group_label>
    <arm_group_label>1.0mg/kg voclosporin</arm_group_label>
    <arm_group_label>1.5mg/kg voclosporin</arm_group_label>
    <arm_group_label>Placebo voclosporin</arm_group_label>
    <other_name>ISA247</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Japanese males and females by birth aged 20 - 45 years inclusive&#xD;
&#xD;
          -  Females who are non-pregnant, non-lactating, and either post-menopausal for at least 1&#xD;
             year, surgically sterile for at least 3 months, or from 35 days prior to study entry&#xD;
             (i.e. Day -2) until 30 days following study completion/discharge and using an approved&#xD;
             method of contraception.&#xD;
&#xD;
          -  Males who are sterile or from the time of dose administration until 30 days following&#xD;
             their dose administration and using an approved method of contraception.&#xD;
&#xD;
          -  Screening FSH &gt;40 IU/ml in self-identified post-menopausal female subjects.&#xD;
&#xD;
          -  Weight must be &gt;55 kg but &lt;100 kg, with BMI of 18-30 kg/m2 inclusive.&#xD;
&#xD;
          -  Healthy as defined by normal screening assessments, including full medical history,&#xD;
             complete physical examination, vital signs, 12-lead ECG, hematology, blood chemistry&#xD;
             and urinalysis. Laboratory results must be within the reference range or considered to&#xD;
             be not clinically significant by the Principal Investigator with agreement of the&#xD;
             Medical Monitor. Lab tests may be repeated during the screening period as appropriate.&#xD;
&#xD;
          -  Capable to participate, provide informed consent and comply with study procedures and&#xD;
             restrictions&#xD;
&#xD;
          -  Must agree to refrain from consumption of grapefruit juice from at least one week&#xD;
             prior to dosing until all follow-up procedures are completed.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History of drug abuse and/or alcoholism in the previous 2 years.&#xD;
&#xD;
          -  Positive urine drug test, urine cotinine test or alcohol breath test at screening.&#xD;
&#xD;
          -  Positive for Hepatitis B, Hepatitis C or HIV.&#xD;
&#xD;
          -  QTcB &gt;430 msec in males, or QTcB &gt;450 msec in females in 12-lead ECG tracing at&#xD;
             screening.&#xD;
&#xD;
          -  Blood donation within 56 days prior to dosing and plasma donation within 7 days prior&#xD;
             to first dosing.&#xD;
&#xD;
          -  Hemoglobin value &lt; 12 g/dL.&#xD;
&#xD;
          -  Current smokers (smoking cigarettes and other forms of tobacco or nicotine use must be&#xD;
             stopped at least 90 days before screening).&#xD;
&#xD;
          -  History of alcohol consumption averaging more than 2 drinks per day in a week (1 drink&#xD;
             is 12 oz beer, 4 oz wine or 1.5oz of spirits) within 6 months prior to screening.&#xD;
             Alcohol-containing foods or beverages are prohibited within 7 days prior to study&#xD;
             entry and during the entire study duration.&#xD;
&#xD;
          -  Use of any drugs known to inhibit or induce hepatic drug metabolism (i.e. inducers&#xD;
             include barbiturates, carbamazepine, phenytoin, glucocorticoids, rifampin/rifabutin;&#xD;
             inhibitors include antidepressants, cimetidine, diltiazem, erythromycin, ketoconazole,&#xD;
             MAO inhibitors, neuroleptics, verapamil, quinidine) within 30 days prior to&#xD;
             administration of the study medication.&#xD;
&#xD;
          -  Participation in a clinical trial involving the administration of an investigational&#xD;
             or marketed drug within 30 days (90 days for biologics) prior to the first dosing&#xD;
&#xD;
          -  Use of prescription medication within 14 days prior to first dosing or&#xD;
             over-the-counter products (including natural products, vitamins, garlic as supplement)&#xD;
             within 7 days prior to first dosing, except for topical products without systemic&#xD;
             absorption, or is likely to need medication during the study period.&#xD;
&#xD;
          -  Clinically significant abnormal liver function, abnormal renal function, active&#xD;
             tuberculosis (TB), or known history of TB/evidence of old TB if not taking prophylaxis&#xD;
             with isoniazid, current or recent infections, history of hypertension and history of&#xD;
             malignancy.&#xD;
&#xD;
          -  Any reason which, in the opinion of the Principal Investigator or the Sponsor's&#xD;
             medical monitor, would prevent the subject from participating in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MAD VCS Site</name>
      <address>
        <city>Dasmarinas City</city>
        <state>Cavite</state>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>October 20, 2016</study_first_submitted>
  <study_first_submitted_qc>October 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2016</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Calcineurin inhibitor</keyword>
  <keyword>Voclosporin</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

